Abbott Laboratories (ABT) Short-Term Debt issuances (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Short-Term Debt issuances data on file, last reported at $31.0 million in Q1 2026.

• For the quarter ending Q1 2026, Short-Term Debt issuances rose 186.11% year-over-year to $31.0 million; the trailing twelve-month figure through Mar 2026 stood at -$48.0 million (down 433.33% YoY), and the FY2025 full-year result was -$115.0 million, down 15.0% from the prior year.
• Short-Term Debt issuances advanced to $31.0 million in Q1 2026, from -$71.0 million in the prior quarter.
• In the past five years, Short-Term Debt issuances ranged from a high of $111.0 million in Q4 2023 to a low of -$127.0 million in Q1 2024.
• A 5-year average of -$6.8 million and a median of $8.0 million in 2022 frame the typical range for Short-Term Debt issuances.
• Peak annual rise in Short-Term Debt issuances reached 1010.0% in 2023, while the deepest fall reached 625.0% in 2023.
• Tracing ABT's Short-Term Debt issuances over 5 years: stood at $10.0 million in 2022, then jumped by 1010.0% to $111.0 million in 2023, then slumped by 76.58% to $26.0 million in 2024, then plunged by 373.08% to -$71.0 million in 2025, then jumped by 143.66% to $31.0 million in 2026.
• Business Quant data shows ABT's Short-Term Debt issuances at $31.0 million in Q1 2026, -$71.0 million in Q4 2025, and $8.0 million in Q3 2025.